Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Globe Newswire (Thu, 5-Feb 8:00 AM ET)
Ardelyx Receives New Patent for Tenapanor
Globe Newswire (Tue, 3-Feb 8:29 AM ET)
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
Globe Newswire (Wed, 28-Jan 8:29 AM ET)
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Globe Newswire (Fri, 23-Jan 12:56 PM ET)
Ardelyx Sets Bold Growth Target: IBSRELA Revenue Projected to Top $1 Billion by 2029
Market Chameleon (Fri, 9-Jan 5:33 AM ET)
Market Chameleon (Thu, 8-Jan 6:16 AM ET)
Ardelyx Projects Strong Revenue Growth for IBSRELA With $1 Billion Milestone in Sight by 2029
Market Chameleon (Thu, 8-Jan 4:06 AM ET)
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
Globe Newswire (Thu, 8-Jan 8:30 AM ET)
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx trades on the NASDAQ stock market under the symbol ARDX.
As of February 11, 2026, ARDX stock price declined to $7.26 with 3,393,401 million shares trading.
ARDX has a beta of 0.89, meaning it tends to be less sensitive to market movements. ARDX has a correlation of 0.06 to the broad based SPY ETF.
ARDX has a market cap of $1.76 billion. This is considered a Small Cap stock.
Last quarter Ardelyx reported $110 million in Revenue and $.00 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.06.
In the last 3 years, ARDX traded as high as $10.13 and as low as $2.82.
The top ETF exchange traded funds that ARDX belongs to (by Net Assets): XBI, IWM, VTI, VXF, IWO.
ARDX has outperformed the market in the last year with a return of +30.3%, while the SPY ETF gained +15.6%. In the last 3 month period, ARDX beat the market returning +28.5%, while SPY returned +1.8%. However, in the most recent 2 weeks ARDX has underperformed the stock market by returning -8.0%, while SPY returned -0.5%.
ARDX support price is $7.03 and resistance is $7.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARDX shares will trade within this expected range on the day.